Senseonics Holdings, Inc.
https://www.senseonics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Senseonics Holdings, Inc.
JPM Day 1: Abbott Riding In Tandem With Libre 2 Plus & t:slim X2 News
The two diabetes players announced a new integration between their products.
Senseonics See Few Barriers To Adoption For Their Implantable CGM
GLP-1 inhibitors and an ever-shrinking company ecosystem are not issues for the company, according to its CEO.
Minute Insight: Senseonics Eversense E3 CGM Receives CE Mark, Launch Planned For Q3
Sensonics received the CE mark for its next-generation E3 CGM with plans to launch in the third quarter. It will be facing stiff competition from CGM makers Dexcom and Abbott in the European market.
Senseonics Projects Slow Growth In 2022 Despite FDA Approval Of Eversense E3 CGM
Senseonics announced the long-awaited FDA approval of its Eversense E3 implantable CGM, featuring a sensor that lasts up to six months. The company is also developing a one-year version of Eversense and a transmitter-less version, but the stock market is disappointed with its sales projections.
Company Information
- Industry
- Digital Health
-
Medical Devices
- Implantable Devices
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
-
- ASN Technologies, Inc
- Sensors for Medicine and Science, Inc.
- Senseonics, Incorporated
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice